Why BGPT?
logo

Author Review Workspace

Draft versioned claims from your manuscript with linked experiments, exact results, limitations, falsifiability notes, and provenance for reviewers.Know what the science actually supports before you trust the answer.

Press Enter ↡ to import


     Quick Explanation



    Riley J. Mangan is a rising computational genomics scientist with an OpenAlex h-index of 13 (~1,074 citations, 47 works), whose portfolio spans a first-author Cell paper decoding human cis-regulatory evolution via deep learning and major collaborative genomics resources (GENCODE 2025, ape genome sequencing), with emerging work in circadian tumor-immune multiomics.


     Long Explanation



    Publication and Citation Profile

    Riley J. Mangan's OpenAlex record shows 47 works with ~1,074 total citations and an h-index of 13, with a steep recent trajectory: 427 citations in 2024 and 211 in 2025, driven largely by resource papers . The Semantic Scholar view (h-index 7, 227 citations, 16 papers) is narrower, illustrating how author-level metrics vary substantially across databases depending on indexing and name disambiguation.

    Scientific Contributions

    Mangan's signature work is a first-author Cell paper showing that adaptive sequence divergence forged new human neurodevelopmental enhancers, applying Enformer deep learning across 34 haplotypes from modern humans, archaic hominins, and great apes to predict 37,592 lineage-specific cis-regulatory events; luciferase assays in neural stem/progenitor cells validated predictions (9/15 elements active; predicted-versus-observed Pearson R = 0.81), and reciprocal mutagenesis showed a single derived allele creating an SRF motif is necessary and sufficient for a hominin-specific enhancer . Mangan also co-authored the GENCODE 2025 reference annotation (394 citations) and the Nature ape genome sequencing paper (142 citations) , plus a 2025 Cell paper on single-cell epigenomic rewiring in Alzheimer's disease profiling 3.5 million cells from 384 postmortem samples .

    Earlier work includes infant HIV/SIV immunology in rhesus macaques (maternal bNAb selection of resistant variants, breast-milk antibody studies) and cancer biology (TGFΞ² signaling in pancreatic and colon cancer). The 2026 circadian breast cancer preprintβ€”time-resolved single-nucleus multiome of 101,321 nuclei across four circadian time points, with cross-species validation in 76 human TNBC samplesβ€”proposes epithelial-immune circadian misalignment as a mechanism of immune evasion and chronotherapy target, though it lacks spatial transcriptomics, prospective human interventional data, and must bridge nocturnal mouse to diurnal human circadian biology .

    Assessment and Blindspots

    Mangan demonstrates unusual breadth: rigorous experimental validation (luciferase assays, reciprocal mutagenesis) alongside computational methods development (the Gonomics Go library for genomics ). The 2026 preprint discloses research funding from Lilly, Pfizer, and Novartis and advisory roles at GE Healthcare and Carrick Therapeuticsβ€”industry entanglements worth noting when evaluating chronotherapy-adjacent claims . Key uncertainties: the deep-learning linCRE approach depends on Enformer's accuracy in untested cellular contexts (validated in only NSPCs), and the enrichment effect near human-upregulated DEGs is modest (log2 enrichment = 0.13) . Overall, this is an early-career (postdoctoral-stage) scientist with a first-author Cell paper, co-authorships on flagship community resources, growing visibility, and a trajectory consistent with continued high-impact workβ€”confidence in this assessment is moderate given limited independent bibliometric verification.



    Feedback:   

    Updated: September 13, 2026

    BGPT Author Review



    Scientific Quality

    60%

    Early-career but demonstrably strong: first-author Cell paper with genuine experimental validation, co-authorship on GENCODE and Nature ape-genome resources, and methods software development. h-index 13 (OpenAlex) is modest and inflated by large consortium papers; independent scientific leadership is still emerging. The deep-learning-to-validated-mechanism pipeline in the Cell paper is the clearest evidence of real scientific skill.



    Communication Quality

    70%

    Papers report clear designs, defined falsification criteria, deposited code and data (GitHub, Zenodo, GEO), and honest reporting of counterevidence (e.g., noting the chimpanzee mutant did not reach full human activity). Communication breadth beyond specialist venues is unverified from the supplied record.



    Author Novelty

    70%

    The sequence-to-function deep learning framework for cis-regulatory evolution, including the single-variant SRF enhancer finding and demonstration that functional divergence often occurs without elevated sequence divergence, is genuinely novel; the circadian tumor-immune work is an emerging but increasingly crowded area.



    Scientific Rigor

    80%

    Strong: explicit statistical thresholds (FDR<0.01, |log2FC|>1), reciprocal mutagenesis with paired statistics and multiple-testing correction, cross-species validation, and transparent limitation reporting (34.9% of linCREs below-average divergence; NSPC-only validation). Preprint lacks spatial and interventional data but self-identifies these gaps.

     Hypothesis Graveyard



    Human-specific traits arise mainly from conserved-region divergence (HARs): falsified in part by Mangan's finding that most functional regulatory divergence occurs in novel elements outside conserved regions and without elevated sequence divergence.


    Maternal bNAbs reliably protect infants from HIV: contradicted by Mangan's co-authorship showing maternal bNAbs can select for neutralization-resistant transmitted/founder variants.

     Science Art


    Author Review: Riley J Mangan Science Art

     Science Movie



    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT